Agios Pharmaceuticals Management

Management criteria checks 3/4

Agios Pharmaceuticals' CEO is Brian Goff, appointed in Aug 2022, has a tenure of 2.33 years. total yearly compensation is $3.42M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €2.67M. The average tenure of the management team and the board of directors is 2.9 years and 7.7 years respectively.

Key information

Brian Goff

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage	23.4%
CEO tenure	2.3yrs
CEO ownership	0.1%
Management average tenure	2.9yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Goff's remuneration changed compared to Agios Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$674m
Jun 30 2024	n/a	n/a	-US$365m
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Compensation vs Market: Brian's total compensation ($USD3.42M) is above average for companies of similar size in the German market ($USD1.58M).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Goff (55 yo)

2.3yrs

Tenure

US$3,416,453

Compensation

Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. since June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. since August 08, 2022. He had be...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% € 2.7m
Cecilia Jones	Chief Financial Officer	2.3yrs	US$1.21m	0.035% € 684.4k
James Burns	Corporate Secretary & Chief Legal Officer	2.9yrs	US$1.93m	0.028% € 533.0k
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	3.3yrs	US$2.87m	0.077% € 1.5m
Tsveta Milanova	Chief Commercial Officer	1.9yrs	US$3.73m	0.023% € 449.3k
Lewis Cantley	Founder	no data	US$333.51k	no data
Tak Mak	Founder	no data	no data	no data
Craig Thompson	Founder	no data	no data	no data
Shin-San Su	Founder	no data	no data	no data
T. Washburn	VP, Controller & Principal Accounting Officer	3.3yrs	no data	0.0014% € 27.7k
Clive Patience	Chief Technical Operations Officer	7.5yrs	no data	no data
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	no data	no data

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: 8AP's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% € 2.7m
Jacqualyn Fouse	Chair of the Board of Directors	7yrs	US$447.25k	0.25% € 4.8m
Jeffrey Capello	Independent Director	1.5yrs	US$663.68k	0.0035% € 67.0k
Marc Tessier-Lavigne	Member of Scientific Advisory Board	8.3yrs	US$302.85k	no data
Charles Sawyers	Member of Scientific Advisory Board	15.8yrs	no data	no data
Kaye Foster-Cheek	Lead Independent Director	10yrs	US$440.95k	0.013% € 256.3k
David Schenkein	Independent Director	15.3yrs	US$417.25k	0.83% € 16.2m
Joan Brugge	Member of Scientific Advisory Board	no data	no data	no data
Matthew Vander Heiden	Member of Scientific Advisory Board	16.1yrs	no data	no data
Scott Biller	Member of Scientific Advisory Board	3.9yrs	US$3.21m	no data
Cynthia Smith	Independent Director	2.3yrs	US$419.91k	0.014% € 271.2k
Ralph Deberardinis	Member of Scientific Advisory Board	no data	no data	no data

7.7yrs

Average Tenure

64yo

Average Age

Experienced Board: 8AP's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 22:02
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Lawson	Barclays
George Farmer	BMO Capital Markets Equity Research
Alec Stranahan	BofA Global Research

Agios Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Recent updates

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.69 loss per share (vs US$1.51 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023)

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022)

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022)

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022)

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Insider recently sold €158k worth of stock

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Full year 2020 earnings released: US$4.75 loss per share (vs US$6.86 loss in FY 2019)

Revenue beats expectations

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

New 90-day high: €47.53

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

New 90-day high: €40.87

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.